February 6, 2017 / 6:57 AM / 7 months ago

BRIEF-Tigenix announces positive results of ADMIRE-CD pivotal phase III trial of Cx601

Feb 6 (Reuters) - Tigenix NV :

* Announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO

* Positive results of ADMIRE-CD pivotal phase III trial of Cx601 for complex perianal fistulas in Crohn's disease patients

* Data demonstrated that remission produced in these hard-to-treat fistulas by Cx601, a suspension of allogeneic adipose-derived stem cells (eASC), was maintained long-term

* Results also support favorable tolerability of Cx601 over long-term - Dr. Marie Paule Richard, Chief Medical Officer at Tigenix

* Has an exclusive licensing and commercialization agreement for Cx601, ex-US, with Takeda and expects a decision from the EMA regarding its marketing authorization by year-end 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below